CorMedix (CRMD) Tops Q3 EPS by 83c

CorMedix (NASDAQ: CRMD) reported Q3 EPS of $1.26, $0.83 better than the analyst estimate of $0.43. Revenue for the quarter came in at $104.28 million versus the consensus estimate of $65.92 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• Iran Has Resumed Producing Ballistic Missiles, U.S. and Middle East Officials Say - WSJ
• American Eagle Outfitters (AEO) PT Lowered to $16 at TD Cowen
• ECB Officials Expect More Tightening With October In Play - Bloomberg